These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10066944)

  • 41. [Status quo and problems in phase III trials: view of a trialist].
    Hamajima N
    Gan To Kagaku Ryoho; 1995 Feb; 22(3):319-22. PubMed ID: 7880101
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Phase III study].
    Furuse K
    Gan To Kagaku Ryoho; 1995 Apr; 22(5):611-5. PubMed ID: 7717712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase III trials: specific problems associated with the use of a placebo control group.
    Cleophas TJ; Van der Meulen J; Kalmansohn RB
    Int J Clin Pharmacol Ther; 1997 Feb; 35(2):47-50. PubMed ID: 9147706
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Interim analyses].
    Kramar A; Paoletti X
    Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent reminders of why the gold standard for clinical research in oncology is the well-designed and conducted randomized phase III trial.
    Markman M
    Curr Oncol Rep; 2004 Nov; 6(6):421-2. PubMed ID: 15485610
    [No Abstract]   [Full Text] [Related]  

  • 46. Parallel paths to predictive biomarkers in oncology: Uncoupling of emergent biomarker development and phase III trial execution.
    Sikorski R; Yao B
    Sci Transl Med; 2009 Dec; 1(10):10ps11. PubMed ID: 20368158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epidemiological factors in clinical trial design.
    Wassilak S
    Dev Biol Stand; 1998; 95():75-83. PubMed ID: 9855417
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect and efficacy--on the function of models in controlled phase III trials and the need for prospective pharmacoepidemiological studies.
    Winterer G; Herrmann WM
    Pharmacopsychiatry; 1996 Jul; 29(4):135-41; discussion 142-3. PubMed ID: 8858712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Test and power considerations for multiple endpoint analyses using sequentially rejective graphical procedures.
    Bretz F; Maurer W; Hommel G
    Stat Med; 2011 Jun; 30(13):1489-501. PubMed ID: 21290405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pitfalls in the interpretation of randomised controlled trials].
    Ueda S
    Masui; 2011 Mar; 60(3):277-84. PubMed ID: 21485096
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Megatrials are based on a methodological mistake.
    Charlton BG
    Br J Gen Pract; 1996 Jul; 46(408):429-31. PubMed ID: 8776917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The scientific basis of clinical trials: statistical aspects.
    Gehan EA
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2587-90. PubMed ID: 9815661
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
    Vickers AJ; Ballen V; Scher HI
    Clin Cancer Res; 2007 Feb; 13(3):972-6. PubMed ID: 17277252
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of toxicity: statistical considerations.
    Herson J
    Cancer Treat Rep; 1980; 64(2-3):463-8. PubMed ID: 7407785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Up-front versus sequential randomizations for inference on adaptive treatment strategies.
    Ko JH; Wahed AS
    Stat Med; 2012 Apr; 31(9):812-30. PubMed ID: 22362642
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Field assays with anti-malarial vaccines: phase III protocols.
    Sanchez T
    Rev Inst Med Trop Sao Paulo; 1992 Apr; 34 Suppl 9():S24-7. PubMed ID: 1340629
    [No Abstract]   [Full Text] [Related]  

  • 59. Statistical methodology of phase III cancer clinical trials: advances and future perspectives.
    Sylvester R; Van Glabbeke M; Collette L; Suciu S; Baron B; Legrand C; Gorlia T; Collins G; Coens C; Declerck L; Therasse P
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S162-8. PubMed ID: 11858987
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
    Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
    Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.